Skip to main content
Fig. 5 | Journal of Experimental & Clinical Cancer Research

Fig. 5

From: TRPM7 silencing modulates glucose metabolic reprogramming to inhibit the growth of ovarian cancer by enhancing AMPK activation to promote HIF-1α degradation

Fig. 5

The shifting glycolysis to OXPHOS by TRPM7 silencing is abrogated or mitigated by HIF-1α over-expression or AMPK inhibition in ovarian cancer cells. HIF-1α over-expression abrogated the TRPM7 silencing-promoted glycolysis in ovarian cancer cells, determined by the glucose uptake (A), lactic acid production (B) and ECAR (C). Treatment with CC (20 μM) to inhibit AMPK activation mitigated the TRPM7 silencing-induced OXPHOS in ovarian cancer cells, determined by the ATP levels (D), ROS levels (E), NAD+/NAPH ratios (F) and OCR (G)

Back to article page

Journal of Experimental & Clinical Cancer Research

ISSN: 1756-9966

Contact us